- Issuer ticker
-
BBOT
- Reported as of
-
10 May 2026
- Net transaction value
-
$0
- SEC form
-
4
- Accepted by SEC
-
12 May 2026, 16:11:42 UTC
Filing notes and source
Key filing fact
Pedro Beltran filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 12 May 2026.
Key facts
- This page summarizes Pedro Beltran's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 May 2026, 16:11.
Change
- Previous filing in this sequence was filed on 05 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0002058152
Primary reporting owner
Beltran Pedro
- Relationship
-
President and CEO, Director
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBOT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +1,103,837
- Change %
- Price
-
$0.000000*
- Shares after
- 1,103,837
- Date
- 10 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,103,837
- Exercise price
- $7.66
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote
SEC remarks
Exhibit 24 - Power of Attorney